Find Reports
Select Report Type
Reimbursement Review
Displaying 351 - 375 of 1258
Please scroll or swipe to the right to view the full content.
| Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|
| Lokelma | sodium zirconium cyclosilicate | Hyperkalemia, adults | Do not reimburse | Complete | SR0612-000 | |||
| Onstryv | safinamide | Parkinson's disease | Do not reimburse | Complete | SR0617-000 | |||
| Monoferric | Iron (III) Isomaltoside 1000 | iron deficiency anemia | Reimburse with clinical criteria and/or conditions | Complete | SR0622-000 | |||
| Taltz | ixekizumab | Ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | SR0630-000 | |||
| Lonsurf | Trifluridine-Tipiracil | Gastric Cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0197-000 | |||
| Darzalex | Daratumumab | Rd for MM | Reimburse with clinical criteria and/or conditions | Complete | PC0189-000 | |||
| Vyndaqel | tafamidis | transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | SR0625-000 | |||
| Trintellix | vortioxetine hydrobromide | Major depressive disorder (MDD), adults. | Reimburse with clinical criteria and/or conditions | Complete | SR0611-000 | |||
| Rinvoq | upadacitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | SR0614-000 | |||
| Tecentriq | Atezolizumab | Small Cell Lung Cancer (SCLC) | Do not reimburse | Complete | PC0156-000 | |||
| Lorbrena | Lorlatinib | Non-Small Cell Lung Cancer (NSCLC) | Do not reimburse | Complete | PC0183-000 | |||
| Kadcyla | Trastuzumab Emtansine | Early Breast Cancer (EBC) | Reimburse | Complete | PC0182-000 | |||
| Libtayo | Cemiplimab | Advanced Cutaneous Squamous Cell Carcinoma (CSCC) | Reimburse with clinical criteria and/or conditions | Complete | PC0187-000 | |||
| Baqsimi | glucagon | Severe hypoglycemic reactions | Reimburse with clinical criteria and/or conditions | Complete | SR0626-000 | |||
| Keytruda | Pembrolizumab | Squamous NSCLC | Reimburse with clinical criteria and/or conditions | Complete | PC0176-000 | |||
| Tegsedi | inotersen | hereditary transthyretin amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | SR0603-000 | |||
| Lynparza | Olaparib | Newly Diagnosed OC | Reimburse with clinical criteria and/or conditions | Complete | PC0174-000 | |||
| Nerlynx | Neratinib | ERBB2-positive breast cancer | Do not reimburse | Complete | PC0172-000 | |||
| Cimzia | certolizumab pegol | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | SR0587-000 | |||
| Revestive | teduglutide | Short Bowel Syndrome (SBS), pediatrics | Reimburse with clinical criteria and/or conditions | Complete | SR0606-000 | |||
| Takhzyro | lanadelumab | Hereditary angioedema, prevention | Reimburse with clinical criteria and/or conditions | Complete | SR0618-000 | |||
| Verkazia | cyclosporine | Severe vernal keratoconjunctivitis, pediatric (≥4 years) | Reimburse with clinical criteria and/or conditions | Complete | SR0615-000 | |||
| Vitrakvi | Larotrectinib | NTRKplus solid tumours | Do not reimburse | Complete | PC0159-000 | |||
| Idhifa | Enasidenib | Acute myeloid leukemia (AML) | Do not reimburse | Complete | PC0144-000 | |||
| Xultophy | insulin degludec + liraglutide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | SR0599-000 |
Health Technology Review
Displaying 351 - 375 of 589
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 111 of 111
Projects in Progress
Displaying 26 - 40 of 40
View All Reports
Displaying 351 - 375 of 2093
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| Bayesian Hierarchical Models of Basket Trials in the Context of Economic Evaluation | Health Technology Review | Technology Review | Completed | MH0020-000 | |||
| Alemtuzumab, Cladribine, Fingolimod, and Natalizumab as First-Line Treatments in Adult Patients With Highly Active Relapsing Multiple Sclerosis | Health Technology Review | Health Technology Assessment | Completed | HT0038-000 | |||
| Pharmaceutical Reviews Update — Issue 47 | Reimbursement Review | Pharmaceutical Review Update | |||||
| von Willebrand Factor [recombinant] | Reimbursement Review | Complete | ST0639-000 | ||||
| Utilization of Antidiabetic Drugs During Pregnancy | Health Technology Review | Technology Review | In Progress | HC0083-000 — OS0007-000 | |||
| Drugs for Metastatic Renal Cell Carcinoma: Utilization Analysis | Health Technology Review | Technology Review | Active | HC0082-000 | |||
| Newborn Screening for Congenital Cytomegalovirus in Canada | Congenital cytomegalovirus (cCMV) infection is a leading cause of childhood hearing loss. Our report provides a summary about newborn screening for cCMV in Canada, including whether screening is available in each province and territory, and if so, whether screening is universal or targeted. | Health Technology Review | Policy Insight | Completed | CY0016-000 | ||
| Colorectal cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0044-000 | |||
| ibrutinib | Reimbursement Review | Not filed | NS0005-000 | ||||
| ibrutinib | Reimbursement Review | Not filed | NS0004-000 | ||||
| Newborn Screening for Congenital Cytomegalovirus | Health Technology Review | Rapid Review | Completed | RC1533-000 | |||
| Exploration of the Risk of Suicidality and Self-Harm With Glucagon-Like Peptide-1 Receptor Agonists | Health Technology Review | Technology Review | Completed | HC0087-000 | |||
| letermovir | Reimbursement Review | Withdrawn | SR0824-000 | ||||
| odevixibat | Reimbursement Review | Complete | SR0788-000 | ||||
| Use of MRI and CT in Private Imaging Facilities in Canada (2021-2023) | Health Technology Review | CMII Service | Completed | CM0010-000 | |||
| General Ultrasound Examination Volumes per Sonographer 8-Hour Workday | Health Technology Review | CMII Service | Completed | CM0012-000 | |||
| nivolumab and relatlimab | Reimbursement Review | Complete | PC0329-000 | ||||
| Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma | Reimbursement Review | Therapeutic Review | Complete | TR0014-000 - OP0547-000 | |||
| Outpatient Nirmatrelvir-Ritonavir and Remdesivir Utilization in Canada | Health Technology Review | Technology Review | Completed | HC0069-000 | |||
| Artificial Intelligence for Patient Flow | Our Horizon Scan explores artificial intelligence-based patient flow management tools that forecast and monitor patient movements from admission to discharge as they progress through different care settings. | Horizon Scan | Emerging Health Technologies | Completed | EH0125-000 | ||
| Efficacy and Safety of Long-Term Use of Omalizumab for the Treatment of Chronic Idiopathic Urticaria | Health Technology Review | Systematic Review | Active | RE0043-000 | |||
| Halobetasol propionate and tazarotene | Reimbursement Review | Complete | SR0638-000 | ||||
| difelikefalin | Reimbursement Review | Complete | SR0752-000 | ||||
| tisagenlecleucel | Reimbursement Review | Complete | PG0306-000 | ||||
| crisantaspase recombinant | Reimbursement Review | Complete | PC0301-000 |